Brokerages expect that Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) will post earnings of ($0.21) per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Ironwood Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.30) and the highest estimate coming in at ($0.16). Ironwood Pharmaceuticals posted earnings of ($0.12) per share during the same quarter last year, which would indicate a negative year over year growth rate of 75%. The firm is expected to issue its next earnings report before the market opens on Thursday, February 15th.
On average, analysts expect that Ironwood Pharmaceuticals will report full year earnings of ($1.11) per share for the current fiscal year, with EPS estimates ranging from ($1.17) to ($1.04). For the next year, analysts anticipate that the firm will post earnings of ($0.50) per share, with EPS estimates ranging from ($0.61) to ($0.29). Zacks’ EPS calculations are an average based on a survey of sell-side research firms that cover Ironwood Pharmaceuticals.
A number of analysts have recently commented on IRWD shares. ValuEngine downgraded Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, November 14th. Credit Suisse Group started coverage on Ironwood Pharmaceuticals in a research note on Monday, November 27th. They issued a “buy” rating and a $19.00 target price on the stock. Morgan Stanley restated a “hold” rating on shares of Ironwood Pharmaceuticals in a research note on Monday, December 4th. Mizuho downgraded Ironwood Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $20.00 to $16.00 in a research note on Wednesday, December 6th. Finally, BidaskClub downgraded Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, December 7th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the company. Ironwood Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $17.56.
In other Ironwood Pharmaceuticals news, CEO Peter M. Hecht sold 113,405 shares of the stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $15.12, for a total transaction of $1,714,683.60. Following the transaction, the chief executive officer now owns 4,696,917 shares in the company, valued at $71,017,385.04. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Mark G. Currie sold 60,000 shares of the stock in a transaction that occurred on Wednesday, January 24th. The stock was sold at an average price of $15.45, for a total value of $927,000.00. Following the transaction, the insider now owns 835,000 shares in the company, valued at approximately $12,900,750. The disclosure for this sale can be found here. Insiders have sold 174,905 shares of company stock worth $2,666,359 in the last quarter. 7.63% of the stock is currently owned by company insiders.
Hedge funds have recently modified their holdings of the business. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Ironwood Pharmaceuticals by 128.6% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,010 shares of the biotechnology company’s stock worth $135,000 after purchasing an additional 5,069 shares in the last quarter. Gerber Kawasaki Wealth & Investment Management purchased a new position in Ironwood Pharmaceuticals during the third quarter worth approximately $170,000. Hemenway Trust Co LLC purchased a new position in Ironwood Pharmaceuticals during the fourth quarter worth approximately $204,000. Ameritas Investment Partners Inc. boosted its position in Ironwood Pharmaceuticals by 5.8% during the second quarter. Ameritas Investment Partners Inc. now owns 11,821 shares of the biotechnology company’s stock worth $223,000 after purchasing an additional 648 shares in the last quarter. Finally, Virtu KCG Holdings LLC boosted its position in Ironwood Pharmaceuticals by 10.3% during the second quarter. Virtu KCG Holdings LLC now owns 15,740 shares of the biotechnology company’s stock worth $297,000 after purchasing an additional 1,470 shares in the last quarter.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.